GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from prevention and screening, to diagnosis, treatment, therapy, and monitoring. We are an $18 billion business with 51,000 employees working to create a world where healthcare has no limits.

With the integration of Samsung's state-of-the-art technologies in the field of IT, image signal processing, semiconductors, and communications, Samsung is committed to creating a new future for medical professionals and patients with a mission to bring health and well-being to people's lives as well as by supporting life-long healthcare for women by pursuing innovative healthcare solutions in Ob/Gyn ultrasound.

Ultrasound machines and AI diagnostic technologies are developed in radiology, OB/GYN, orthopedics and etc. for fast and accurate diagnosis. In addition, clinical research activities are also performed with worldwide prestigious KOLs to enhance and improve diagnostics in these various applications.

Samsung will continue to focus on and innovate to provide new experiences that go beyond what medical professionals and patients have experienced before.

Samsung will always be there to build a healthier future with continuous research and innovations.

Canon Medical offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound and MRI, across the globe. As of December 2016, Canon Medical became a member of the Canon Group. In line with our continued Made For life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features.

At Canon Medical we work hand in hand with our partners – our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life.

B·R·A·H·M·S GmbH, part of Thermo Fisher Scientific, investigates, develops and manufactures novel diagnostic testing procedures to improve early diagnosis and treatment of life-threatening diseases. With high-quality immunodiagnostic tests for prenatal screening, pre-eclampsia and other disorders, the company contributes to the creation of a healthier future – to the greatest advantage for medical professionals and patients.

In future simple and economic blood tests will be of great importance for an early detection and successful treatment of diseases. With our know-how and technologies we are confident to play an active role in this future: Our products provide important information to clinicians and laboratories in more than 130 countries worldwide, supporting their clinically and economically relevant decisions.

The B·R·A·H·M·S KRYPTOR platforms and the B·R·A·H·M·S biomarkers for prenatal screening are IVDR compliant and approved by the Fetal Medicine Foundation (FMF), the portfolio comes up to the quality standards of the FMF since 1999.

At Illumina, our mission is to improve human health by unlocking the power of the genome. Our sequencing by synthesis chemistry is used to generate high-accuracy DNA and RNA sequence data in studies around the globe. Our microarrays also provide accurate, high-throughput genotyping for a range of applications. Through innovation and collaboration with health care providers and clinical laboratories, we are enabling genomic breakthroughs and using whole-genome sequencing to shorten the patient diagnostic odyssey. At Illumina, we support global efforts for projects that create equitable genome representation, so all populations can benefit from the full health potential of genomic research. We’re empowering our partners to predict and prevent disease, make personalized medicine a reality, and help people understand more about themselves. And this is only the beginning.

Diagnoly is a MedTech company that helps practitioners detect fetal abnormalities, reduce risk, and perform safer, faster, and more consistent ultrasound exams with greater confidence.

Your trusted real-time AI ultrasound assistant provides a second set of expert eyes to deliver a complete, reliable scan. Fetoly, our medical AI application, performs real-time analysis, validates exam completeness, and flags suspicious measurements. While our solution helps improve workflow efficiency and exam quality in your clinic, it remains fully compatible with major ultrasound systems and runs locally with no cloud services, giving you full control over your data.

In the end, Diagnoly reinforces clinical assurance and provides patients with more comfort and trust during prenatal care.

Pregnolia AG is a Swiss medical technology company developing an innovative diagnostic platform to support clinicians in obstetrics. Pregnolia has created a proprietary, CE-marked point-of-care device that accurately measures cervical stiffness, helping clinicians better understand the biomechanical status of the cervix throughout pregnancy. The aim is to improve risk assessment and management in areas such as preterm labour and induction of labour.

Origin Medical, headquartered in Cambridge, Massachusetts, USA, is driven by a mission to advance maternal health equity by improving access to quality prenatal care with artificial intelligence.

By combining the knowledge of healthcare and AI, it is on a journey to build state-of-the-art solutions aimed at supporting a broad spectrum of healthcare providers in rural and urban communities, allowing them to practice at the top of their licenses. With AI in the imaging workflow, clinicians can more confidently deliver timely interventions, enhance pregnancy outcomes, identify high-risk pregnancies to reduce maternal mortality, and significantly lower infant mortality rates.

At Revvity, “impossible” is inspiration, and "can’t be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialization in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With more than $3 billion in revenue and over 11,000 employees, Revvity serves customers across pharma and biotech, diagnostic labs, academia and governments. Revvity is part of the S&P 500 index and has customers in more than 190 countries.

Revvity products were chosen as the principal screening tool for the ASPRE study. Throughout the study, the Revvity’s DELFIA® Xpress PlGF 1-2-3TM assay was used as an aid in screening for pre-eclampsia in conjunction with maternal history, mean arterial blood pressure (MAP) measurement, and uAD (Uterine Artery Doppler). In 2022, Revvity’s DELFIA® Xpress PlGF 1-2-3TM and DELFIA® Xpress sFlt-1/PlGF Ratio were approved for inclusion in NICE DG-49 diagnostic guidance “PlGF based testing to help diagnose suspected preterm preeclampsia.”

To help facilitate wider access to non-invasive prenatal testing for pregnant women, Revvity offers an easy to use, cost-effective, high-throughput screening system. The Vanadis® cfDNA system is an automated non-sequencing, non-PCR based solution for cfDNA analysis.